Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).

Phase 2 Completed 103 enrolled Grifols, S.A.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase 2, multi-site, double-masked, randomized, vehicle-controlled, study designed to evaluate the safety, tolerability, and efficacy in adult participants with DED.

Timeline

Start: 2025-11-03
Primary completion: 2026-05-20
Completion: 2026-05-20

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GRF312	Unknown	5 %	Other

Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).

Summary

Timeline

Drugs

Indications